甲癣治疗市场：依治疗方法、类型和地区划分

据估计，2026年甲癣治疗市场价值为37.55亿美元，预计到2033年将达到54.97亿美元。预计从2026年到2033年，该市场将以5.6%的复合年增长率成长。

甲癣是一种真菌感染疾病，会影响脚趾甲或手指甲，甚至可能影响指甲的任何组成部分。由于其疗效显着，治疗仍是首选治疗方法。新一代口服抗真菌药物（Itraconazole和Terbinafine）正在取代传统的甲癣治疗方法。

市场动态

糖尿病患者患甲癣的风险增加、糖尿病盛行率上升、老年人口增长、对安全有效治疗方法的需求增加、对开发新的甲癣治疗方法的日益关注，以及公众对甲癣潜在威胁和可用治疗方法的认识提高，是预计在预测期内推动全球甲癣治疗市场增长的主要因素。

例如，2021 年 4 月，Alembic Pharmaceuticals Limited（Alembic）宣布，其合资企业 Aleor Dermaceuticals Limited（Aleor）已获得美国食品药物管理局(FDA) 对其用于治疗脚趾甲真菌的 efinaconazole脚指溶液的简略新药申请 (ANDA) 的临时核准。

此外，2020年10月，Mundipharma在其BETADINE系列感染疾病治疗产品中推出了一款新产品。这款BETADINE EMTRIX指甲抗霉菌溶液能有效治疗甲癣，且长期使用可改善指甲外观。

本报告的主要特点

• 本报告对全球甲癣治疗市场进行了详细分析，包括预测期（2026-2033 年）的市场规模和复合年增长率，以 2025 年为基准年。
• 此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本节根据以下参数，对全球甲癣治疗市场的主要企业进行介绍：公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
• 《全球甲癣治疗市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过分析全球甲癣治疗市场中使用的各种策略矩阵来促进决策。

目录

第一章：分析目标与假设

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 全球甲癣（指甲真菌感染）的盛行率正在上升。
  • 替代治疗方法的选择增多
  • 对安全有效的甲癣治疗方法的需求日益增长
• 影响分析
• 主要亮点
• 法规环境
• 产品上市及核准
• PEST分析
• 波特五力分析
• 企业合併趋势

第四章 全球甲癣治疗市场：依治疗方法（2020-2033 年）

• 製药
• 雷射疗法
• 动态疗法

第五章 全球甲癣治疗市场：按类型划分（2020-2033 年）

• 远端边缘甲下真菌病
  • 介绍
  • 市场规模、预测及年增速
• 表白灰指甲
  • 介绍
  • 市场规模、预测及年增速
• 灰指甲
  • 介绍
  • 市场规模、预测及年增速
• 其他类型
  • 介绍
  • 市场规模、预测及年增速

第六章 全球甲癣治疗市场：按地区划分（2020-2033 年）

• 北美洲
  • 介绍
  • 市场规模及预测、年增长率（YoY）：依治疗方法划分
  • 市场规模及预测、年增速（YoY）：依类别划分
• 我们
• 加拿大
• 欧洲
  • 介绍
  • 市场规模及预测、年增长率（YoY）：依治疗方法划分
  • 市场规模及预测、年增速（YoY）：依类别划分
• 英国
• 德国
• 法国
• 其他欧洲国家
• 亚太地区
  • 介绍
  • 市场规模及预测、年增长率（YoY）：依治疗方法划分
  • 市场规模及预测、年增速（YoY）：依类别划分
• 中国
• 日本
• 澳洲
• 印度
• ASEAN
• 韩国
• 其他亚太地区
• 拉丁美洲
  • 介绍
  • 市场规模及预测、年增长率（YoY）：依治疗方法划分
  • 市场规模及预测、年增速（YoY）：依类别划分
• 墨西哥
• 巴西
• 其他拉丁美洲
• 中东
  • 介绍
  • 市场规模及预测、年增长率（YoY）：依治疗方法划分
  • 市场规模及预测、年增速（YoY）：依类别划分
• 波湾合作理事会（GCC）国家
• 非洲
  • 介绍
  • 市场规模及预测、年增长率（YoY）：依治疗方法划分
  • 市场规模及预测、年增速（YoY）：依类别划分
• 南非
• 其他中东和非洲地区

第七章 竞争情势

• Lumenis Ltd.
• Cipla Ltd.
• Bayer AG
• Johnson &Johnson
• Moberg Pharma AB
• Pfizer Inc.
• Novartis
• Galderma SA
• Dr. Reddys Laboratories Ltd.
• Medimetriks Pharmaceuticals Inc.
• Bausch Health Companies Inc.（Valeant Pharmaceuticals Inc.）

第八章

• 分析方法
• 关于 Coherent Market Insights

Onychomycosis Treatment Market is estimated to be valued at USD 3,755 Mn in 2026 and is expected to reach USD 5,497 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For treatment, drugs remain the first-line treatment choice owing to a consistently high success rate. A newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis.

Market Dynamics

Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes, growing geriatric population, increase in demand for safe and effective treatment, rise in focus on the development of novel onychomycosis treatments, and growing awareness among people about potential threats of onychomycosis and available treatments are major factors expected to drive growth of the global onychomycosis treatment market over the forecast period.

For instance, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.

Moreover, in October 2020, Mundipharma launched the latest addition to its BETADINE range of infectious disease therapies. This BETADINE EMTRIX fungal nail solutions effectively treats the onychomycosis and improves the nail appearance after regular application.

Key features of the study

• This report provides in-depth analysis of the global onychomycosis treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global onychomycosis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global onychomycosis treatment market.

Onychomycosis Treatment Market Segmentation

• By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033)
  • Drugs
  • Laser Therapy
  • Photodynamic Therapy
• By Type Insights (Revenue, USD Mn, 2020 - 2033)
  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Other Types
• By Region Insights (Revenue, USD Mn, 2020 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players in the Onychomycosis Treatment Market
  • Lumenis Ltd.
  • Cipla Ltd.
  • Bayer AG
  • Johnson & Johnson
  • Moberg Pharma AB
  • Pfizer Inc.
  • Novartis
  • Galderma SA
  • Reddys Laboratories Ltd.
  • Medimetriks Pharmaceuticals Inc.
  • Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
  • Others.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Type
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of onychomycosis around the world
  • Availability of alternative treatment options
  • Rise in demand for safe/effective onychomycosis treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Onychomycosis Treatment Market, By Treatment Type, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2020 - 2033
  • Segment Trends
• Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Laser Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Photodynamic Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Onychomycosis Treatment Market By Type, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2020 - 2033
  • Segment Trends
• Distal Subungual Onychomycosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• White Superficial Onychomycosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Proximal Subungual Onychomycosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
• Other Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Onychomycosis Treatment Market By Geography, 2020-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2020 - 2033
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
• U.K.
• Germany
• France
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
• China
• Japan
• Australia
• India
• ASEAN
• South Korea
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
• Mexico
• Brazil
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
• GCC
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
• South Africa
• Rest of Middle East, and Africa

7. Competitive Landscape

• Lumenis Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Moberg Pharma AB
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Galderma SA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Dr. Reddys Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Medimetriks Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us